SO
ELVN icon

STRS Ohio’s Enliven Therapeutics ELVN Stock Holding History

STRS Ohio’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,200
Closed -$27K – 1960
2024
Q4 		$27K Hold
1,200
– – ﹤0.01% 1788
2024
Q3 		$30.6K Buy
+1,200
New +$27.8K ﹤0.01% 1864
2021
Q1 		– Sell
-325
Closed -$28K – 2198
2020
Q4 		$28K Hold
325
– – ﹤0.01% 2054
2020
Q3 		$26K Hold
325
– – ﹤0.01% 2058
2020
Q2 		$35K Buy
+325
New +$36.4K ﹤0.01% 1963

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

STRS Ohio's ELVN Position: Q1 2025 in Review

STRS Ohio sold out of Enliven Therapeutics (ELVN) in Q1 2025, closing a stake of 1,200 shares — an estimated $27K sold.

STRS Ohio first reported a position in ELVN in Q2 2020 and held it in 5 quarters. The position peaked at $35K in Q2 2020. 121 funds tracked by Wall St. Rank hold ELVN as of Q1 2025.

  • STRS Ohio reported no remaining Enliven Therapeutics position as of Q1 2025 after selling out during the quarter.
  • STRS Ohio sold 1,200 Enliven Therapeutics shares in Q1 2025, an estimated $27K.
  • STRS Ohio first reported a position in Enliven Therapeutics in Q2 2020 and held it in 5 quarters.
  • STRS Ohio's Enliven Therapeutics position peaked at $35K in Q2 2020.
  • 121 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2025.

Based on STRS Ohio's 13F filing for Q1 2025, filed 28 May 2025.